Welcome to Biolauncher - where science and technology businesses succeed

+44 (0)1865 575 170

How Hard Can It Be?

At first glance life science venture capitalists must have it easy,  given a pile of cash to invest in a huge $1.8T market healthcare market and smart scientists generating new biomedical insights, surely a return on capital is guaranteed?  However as the data from Cambridge Associates and the landmark Kauffman report “WE HAVE MET THE ENEMY… AND HE IS US” show, returns to LPs have been rare over the last decade.

Life Science Venture Fund performance 1990-2009 Source Cambridge Associates, 2010 Benchmark Report

Life Science Venture Fund performance 1990-2009 Source Cambridge Associates, 2010 Benchmark Report

A recent development at Biolauncher has been to work alongside venture firms to help shape their new fund raising strategy based on analysis of global investment trends, industry deal making and future industry needs.  We have also been commissioned by prospective Limited Partners to gather the evidence to support their commitments to new funds.

Through our networks we are connected to a rich network of organisations funding and investing in the life science sector.  We track the development of new fund models that are striving to find better ways of funding innovation critical to the improvement of human health and well being.

Example Projects

  • Evidence base to support a first time LP investment in a UK VC fund
  • Facilitation of strategy workshop to support launch of new Impact Investment Fund
  • Technology, licensing and M&A deal flow search supported by our ShowcaseBio database
  • Portfolio valuation for a secondary transaction
  • Translational funding and investment trends analysis for a major medical research charity
  • Company creation and access to capital trend analysis in UK life science companies